These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
260 related articles for article (PubMed ID: 31704214)
1. Evaluation of super-boosted lopinavir/ritonavir in combination with rifampicin in HIV-1-infected patients with tuberculosis. Boulanger C; Rolla V; Al-Shaer MH; Peloquin C Int J Antimicrob Agents; 2020 Feb; 55(2):105840. PubMed ID: 31704214 [TBL] [Abstract][Full Text] [Related]
2. Coadministration of lopinavir/ritonavir and rifampicin in HIV and tuberculosis co-infected adults in South Africa. Murphy RA; Marconi VC; Gandhi RT; Kuritzkes DR; Sunpath H PLoS One; 2012; 7(9):e44793. PubMed ID: 23028623 [TBL] [Abstract][Full Text] [Related]
3. The safety, effectiveness and concentrations of adjusted lopinavir/ritonavir in HIV-infected adults on rifampicin-based antitubercular therapy. Decloedt EH; Maartens G; Smith P; Merry C; Bango F; McIlleron H PLoS One; 2012; 7(3):e32173. PubMed ID: 22412856 [TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics of lopinavir in combination with rifampicin-based antitubercular treatment in HIV-infected South African children. Elsherbiny D; Ren Y; McIlleron H; Maartens G; Simonsson US Eur J Clin Pharmacol; 2010 Oct; 66(10):1017-23. PubMed ID: 20552180 [TBL] [Abstract][Full Text] [Related]
5. Safety and Pharmacokinetics of Double-Dose Lopinavir/Ritonavir + Rifampin Versus Lopinavir/Ritonavir + Daily Rifabutin for Treatment of Human Immunodeficiency Virus-Tuberculosis Coinfection. Kendall MA; Lalloo U; Fletcher CV; Wu X; Podany AT; Cardoso SW; Ive P; Benson CA Clin Infect Dis; 2021 Aug; 73(4):706-715. PubMed ID: 34398956 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic study of two different rifabutin doses co-administered with lopinavir/ritonavir in African HIV and tuberculosis co-infected adult patients. Kouanda S; Ouedraogo HG; Cisse K; Compaoré TR; Sulis G; Diagbouga S; Roggi A; Tarnagda G; Villani P; Sangare L; Simporé J; Regazzi M; Matteelli A BMC Infect Dis; 2020 Jun; 20(1):449. PubMed ID: 32590942 [TBL] [Abstract][Full Text] [Related]
8. Brief Report: Suboptimal Lopinavir Exposure in Infants on Rifampicin Treatment Receiving Double-dosed or Semisuperboosted Lopinavir/Ritonavir: Time for a Change. Jacobs TG; Mumbiro V; Chitsamatanga M; Namuziya N; Passanduca A; Domínguez-Rodríguez S; Tagarro A; Nathoo KJ; Nduna B; Ballesteros A; Madrid L; Mujuru HA; Chabala C; Buck WC; Rojo P; Burger DM; Moraleda C; Colbers A; ; J Acquir Immune Defic Syndr; 2023 May; 93(1):42-46. PubMed ID: 36724434 [TBL] [Abstract][Full Text] [Related]
9. Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis. Ren Y; Nuttall JJ; Egbers C; Eley BS; Meyers TM; Smith PJ; Maartens G; McIlleron HM J Acquir Immune Defic Syndr; 2008 Apr; 47(5):566-9. PubMed ID: 18197120 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and safety of rifabutin in young HIV-infected children receiving rifabutin and lopinavir/ritonavir. Moultrie H; McIlleron H; Sawry S; Kellermann T; Wiesner L; Kindra G; Gous H; Van Rie A J Antimicrob Chemother; 2015 Feb; 70(2):543-9. PubMed ID: 25281400 [TBL] [Abstract][Full Text] [Related]
11. Leveraging physiologically based pharmacokinetic modeling to optimize dosing for lopinavir/ritonavir with rifampin in pediatric patients. Salerno SN; Capparelli EV; McIlleron H; Gerhart JG; Dumond JB; Kashuba ADM; Denti P; Gonzalez D Pharmacotherapy; 2023 Jul; 43(7):638-649. PubMed ID: 35607886 [TBL] [Abstract][Full Text] [Related]
12. Adoption of evidence-informed guidelines in prescribing protease inhibitors for HIV-Tuberculosis co-infected patients on rifampicin and effects on HIV treatment outcomes in Uganda. Mulindwa F; Castelnuovo B; Kirenga B; Kalibbala D; Haguma P; Muddu M; Semitala FC BMC Infect Dis; 2021 Aug; 21(1):822. PubMed ID: 34399706 [TBL] [Abstract][Full Text] [Related]
13. Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz. Pham PA; Hendrix CW; Barditch-Crovo P; Parsons T; Khan W; Parish M; Radebaugh C; Carson KA; Pakes GE; Qaqish R; Flexner C Antivir Ther; 2007; 12(6):963-9. PubMed ID: 17926651 [TBL] [Abstract][Full Text] [Related]
14. Abacavir Exposure in Children Cotreated for Tuberculosis with Rifampin and Superboosted Lopinavir-Ritonavir. Rabie H; Tikiso T; Lee J; Fairlie L; Strehlau R; Bobat R; Liberty A; McIlleron H; Andrieux-Meyer I; Cotton M; Lallemant M; Denti P Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32071055 [TBL] [Abstract][Full Text] [Related]
15. Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV- infected tuberculosis patients on lopinavir/ritonavir-based antiretroviral therapy. Naiker S; Connolly C; Wiesner L; Kellerman T; Reddy T; Harries A; McIlleron H; Lienhardt C; Pym A BMC Pharmacol Toxicol; 2014 Nov; 15():61. PubMed ID: 25406657 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of plasma lopinavir and ritonavir in tuberculosis-HIV co-infected African adult patients also receiving rifabutin 150 or 300 mg three times per week. Ouedraogo HG; Matteelli A; Sulis G; Compaore TR; Diagbouga S; Tiendrebeogo S; Roggi A; Cisse K; Giorgetti PF; Villani P; Sangare L; Simpore J; Regazzi M; Kouanda S Ann Clin Microbiol Antimicrob; 2020 Jan; 19(1):3. PubMed ID: 31969147 [TBL] [Abstract][Full Text] [Related]
17. Dose optimization with population pharmacokinetics of ritonavir-boosted lopinavir for Thai people living with HIV with and without active tuberculosis. Chaivichacharn P; Avihingsanon A; Gatechompol S; Ubolyam S; Punyawudho B Drug Metab Pharmacokinet; 2022 Dec; 47():100478. PubMed ID: 36375225 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis. Ribera E; Azuaje C; Lopez RM; Domingo P; Curran A; Feijoo M; Pou L; Sánchez P; Sambeat MA; Colomer J; Lopez-Colomes JL; Crespo M; Falcó V; Ocaña I; Pahissa A J Antimicrob Chemother; 2007 Apr; 59(4):690-7. PubMed ID: 17307771 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis. van der Laan LE; Garcia-Prats AJ; Schaaf HS; Tikiso T; Wiesner L; de Kock M; Winckler J; Norman J; McIlleron H; Denti P; Hesseling AC Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133558 [TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics of lopinavir and ritonavir in combination with rifampicin-based antitubercular treatment in HIV-infected children. Zhang C; McIlleron H; Ren Y; van der Walt JS; Karlsson MO; Simonsson US; Denti P Antivir Ther; 2012; 17(1):25-33. PubMed ID: 22267466 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]